Vivos Therapeutics Cuts Debt by $2.86 Million Through Equity Exchange

Key Facts

1Vivos Therapeutics entered into exchange agreements to swap $2.86 million of outstanding debt for common stock.

In a move reflecting a strategic shift toward capital restructuring, Vivos Therapeutics has announced a significant reduction in its debt obligations. According to reports, the company entered into exchange agreements to swap $2.86 million of outstanding debt for common stock, a step aimed at strengthening its balance sheet by converting liabilities into equity.

The transaction involved exchanging $2,861,270 of principal debt under a secured promissory note for 11,445,080 shares of common stock at an exchange price of $0.25 per share. This arrangement with Streeterville Capital is intended to lower the company's debt burden, though the issuance of over 11 million new shares represents a material dilution for existing equity holders.

Regarding market performance, VVOS stood at $0.1864 (close September 4, 2026), having traded between a day low of $0.164 and a high of $0.1893 per market data. Investors are now monitoring upcoming US economic catalysts, including Factory Orders and weekly petroleum reports, which may influence broader sentiment for small-cap healthcare stocks.